Touting superior nasal delivery, Satsuma bags $62M for new formulation of old migraine drug
A single-minded biotech out of South San Francisco has raised $62 million to run the last mile hoping to breath new life into a generic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
